Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06526546 · ClinicalTrials.gov registry record
ADVENT Trial Long Term Outcomes Evaluating Atrial Fibrillation Progression Study
A clinical trial of Paroxysmal Atrial Fibrillation, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- 364
- Enrollment target
- 20
- Study locations
NCT06526546: Completed study of Paroxysmal Atrial Fibrillation, sponsored by Boston Scientific Corporation.
NCT06526546 is a study of Paroxysmal Atrial Fibrillation that has completed, run by Boston Scientific Corporation. The registered enrollment target is 364 participants, below the 844-participant average among 24 other Paroxysmal Atrial Fibrillation trials with a reported enrollment target (57% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06526546, a study of Paroxysmal Atrial Fibrillation, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- 364 participants
- Enrollment target
- 20
- Study locations
Study Summary
The (ADVENT LTO) is an observational, non-significant risk study to assess the progression of atrial fibrillation in subjects who received ablation treatment with either the FARAPULSE Pulsed Field Ablation System or thermal ablation in the ADVENT Trial.
Primary Outcome
Occurrence of any of the following between the end of the Blanking Period (Day 90) in the ADVENT Trial through completion of follow-up in the ADVENT LTO study: Detectable AF, AFL+, or AT * ≥ 30 seconds in duration as adjudicated within the ADVENT Trial * Investigator assessed ≥ 30 seconds in duration from any approved clinical recording devices considered standard of care\* at the study center post-ADVENT Trial completion * ≥ 30 seconds in duration recorded on the Holter monitor collected duri
Conditions Studied
Study Locations (20)
California
- Mills Peninsula Health Services - Burlingame
- Scripps Memorial Hospital - La Jolla
- University of California, San Francisco - San Francisco
Pennsylvania
- Doylestown Hospital - Doylestown
- Presbyterian University of Pennsylvania Medical Center - Philadelphia
- Pinnacle Health at Harrisburg Hospital - Wormleysburg
Massachusetts
- Massachusetts General Hospital (MGH) - Boston
- Beth Israel Deaconess Medical Center - Boston
New York
- Mount Sinai, Icahn School of Medicine - New York
- Northwell Health - New York
Alabama
- Grandview Medical Center - Birmingham
Arizona
- Banner University Medical Center Phoenix - Phoenix
District of Columbia
- Washington Hospital Center - Washington D.C.
Georgia
- Emory University Hospital - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 364 participants |
| Start Date | 2024-10-31 |
| Est. Completion | 2025-12-08 |
What the finished NCT06526546 record still lists
NCT06526546 is an observational study that tracks outcomes without assigning an intervention. The registered 364 participants enrollment target is mid-sized for trials with a published cap, below the 844-participant average among 24 other Paroxysmal Atrial Fibrillation trials with a reported enrollment target (57% lower).
The record links to 1 condition, with Paroxysmal Atrial Fibrillation appearing as the primary indexed condition, and to 0 interventions.
NCT06526546 names 20 study sites across 14 states, led by California, Pennsylvania, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06526546 about?
NCT06526546 is a clinical study titled "ADVENT Trial Long Term Outcomes Evaluating Atrial Fibrillation Progression Study". The (ADVENT LTO) is an observational, non-significant risk study to assess the progression of atrial fibrillation in subjects who received ablation treatment with either the FARAPULSE Pulsed Field Ablation System or thermal ablation in the ADVENT Trial.
What is the current status of trial NCT06526546?
This trial is currently completed. The enrollment target is 364 participants. The study started on 2024-10-31. Estimated completion is 2025-12-08.
What conditions does trial NCT06526546 study?
This clinical trial studies the following conditions: Paroxysmal Atrial Fibrillation.
Who is sponsoring clinical trial NCT06526546?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06526546 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, District of Columbia, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Paroxysmal Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06526546's enrollment target sits among peer trials
364 4th of 24 higher than 21 of 24 other Paroxysmal Atrial Fibrillation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Paroxysmal Atrial Fibrillation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ULTRA-HFIB-Redo: Ultrasound-based Renal Sympathetic Denervation vs Control in Redo Ablation Patients
RECRUITING · NA
-
Determinates of Atrial Tracking and Prevalence of Atrial Fibrillation in the Micra AV2 (DANCE AFIB)
RECRUITING
-
STOP AF First Post-Approval Study
RECRUITING
-
The Long-term Safety and Effectiveness Evaluation of the QDOT MICRO System Use in Conjunction With VISITAG SURPOINT Module for the Treatment of Symptomatic Drug Refractory Paroxysmal Atrial Fibrillation.
RECRUITING
-
EXercise Cardiac Magnetic Resonance Assessment of Left Atrial Mechanics Following Ablation
RECRUITING
-
Biomarker-Guided Optimization of Transcutaneous Vagal Stimulation for Atrial (BiG tVNS-AF)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04510597 · 364 participants · Phase 3
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
- NCT05098132 · 364 participants · Phase 1
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
- NCT05330221 · 364 participants · NA
Project 2: ACHIEVE- HF
- NCT05673148 · 364 participants · Phase 3
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI